standard protocols should be established for treating eligible stroke patients with tissue plasminogen activator (tpa) (recommendation class i, level of evidence b). the iranian standard protocol of intravenous thrombolysis with recombinant tissue plasminogen activator (ivttpa) is the best possible and easy to use method for performing intravenous thrombolysis in iran. this protocol overcomes p...

Supplementary Fig. S2 Rotem analysis. (A) Representative human whole blood thromboelastogram (ROTEM) profiles. Venous blood was preincubated with a sub-threshold recombinant tissue plasminogen activator (rtPA) alone (1.1 nmol/L), rtPA/DLF (1.1 nmol/L), NF alone, DLF alone and rpTF/NF. (B) In each condition, the rate of fibrinolysis was assessed by the reduction of the amplitude of the thromboel...

The case of a 43-year-old Taiwanese man who presented with spinal epidural hematoma following intravenous administration of recombinant tissue plasminogen activator (rTPA) and heparin therapy for acute myocardial infarction (AMI) is reported. Upper back pain and progressive neurological dysfunction ensued, secondary to spinal epidural hematoma with spinal cord compression. The patient did not r...

Ischemic stroke is a major cause of death and disability worldwide. Intravenous administration of recombinant tissue plasminogen activator (rtPA) is the only approved pharmacological therapy for patients with acute ischemic stroke. Treatment with intravenous rtPA is associated with increased rates of intracranial hemorrhage. This review discusses recent findings about the changes of the compone...

We describe three cases of submacular hemorrhage that occurred two to four days after anti-VEGF intravitreal injection for occult choroidal neovascularisation in age-related macular degeneration and their management with 25 gauge pars plana vitrectomy with injection of subretinal recombinant tissue plasminogen activator (rTPA) followed by fluid-air exchange and postoperative prone position. Vit...

BACKGROUND Intravenous recombinant tissue plasminogen activator (IV rtPA) is recommended treatment for acute ischemic stroke patients, but the cost-effectiveness of IV rtPA within different time windows after the onset of acute ischemic stroke is not well reviewed. AIMS To conduct a literature review of the cost-effectiveness studies about IV rtPA by treatment times. SUMMARY OF REVIEW A lit...

Background: Intravenous (IV) recombinant tissue Plasminogen Activator (rtPA) (IV-rtPA) is the only FDA-approved pharmacological therapy for treatment in acute ischemic stroke and the administration of IV-rtPA is crucially time-dependent. Objectives: This study aimed to evaluate symptom-to-needle time and factors associated with the prehospital delay in patients with acute ischemic stroke refer...

We report a case of a patient with hypertension and ischaemic heart disease on anti-platelet treatment, who developed uniocular profound visual loss from a submacular haemorrhage secondary to valsalva retinopathy. He was treated with a combination of intravitreal recombinant tissue plasminogen activator (rtPA) and sulphur hexafluoride (SF6) gas followed by strict prone positioning. He demonstra...

BACKGROUND AND PURPOSE Early thrombolytic therapy with intravenous recombinant tissue plasminogen activator (rtPA) improves clinical outcome in acute ischemic stroke (AIS), but impaired endogenous fibrinolysis, thrombin generation, and vascular injury may hamper the efficacy of thrombolysis. We investigated in an exploratory, post hoc analysis the relationship between hemostatic markers and cli...